KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis.

Andreas Wollenberg, Jonathan I Silverberg, Franz J Legat, Marie Tauber, Vivian T Laquer, April W Armstrong, Andrew E Pink, Luigi Naldi, Grażyna Pulka, Jacek Zdybski, Athanasios Tsianakas, Jorge Diaz, Inese Svarca, Jennifer Beecker, Galina Balakirski, Sylvia Pauser, Liliana Ulianov, Anna Ryzhkova, Jean-Loup Machu, Christophe Piketty

Acta Derm Venereol 106 0085

PMID42272192
PMCIDPMC13253760
DOI10.2340/actadv.v106.adv-2025-0085
发表日期2026-06-11
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

Nemolizumab with background topical therapy (corticosteroids±calcineurin inhibitors) significantly improved skin lesions, itch and sleep in two global phase 3 trials (ARCADIA 1&2) in adolescents and adults with moderate-to-severe atopic dermatitis through week (W)16. Efficacy and safety of nemolizumab, combined with background topical therapy, were evaluated for an additional 32 weeks (W16-W48) with a focus on maintained skin responses in clinical responders (patients achieving Investigator's Global Assessment [IGA] score of 0/1 [clear/almost clear] or ≥75% improvement in Eczema Area and Severity Index [EASI-75] at W16). At W16, clinical responders (N=507) to nemolizumab every 4 weeks (Q4W) were rerandomized (1 : 1 : 1) to receive nemolizumab 30 mg-Q4W/-Q8W/placebo (nemolizumab-withdrawal) subcutaneously with background topical therapy. At W48, 61.5% (strata-adjusted difference versus nemolizumab-withdrawal group [Δ], 11.8% [95% CI 1.3-22.3]) and 76.3% (Δ, 12.4% [95% CI 2.7- 22.0]) of patients in nemolizumab-Q4W; 60.4% (Δ, 10.7% [95% CI 0.3-21.0]) and 75.7% (Δ, 11.8% [95% CI 2.1-21.5]) in nemolizumab-Q8W; and 49.7% and 63.9% in nemolizumab-withdrawal group maintained response rate for IGA success and EASI-75, respectively. The percentage of patients who experienced ≥1 adverse events were similar across the groups (range: 53.5%-58.3%). Up to W48, skin responses were maintained without notable differences in the safety profile of both nemolizumab dosing regimens.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 1.

Response rate for IGA success a and EASI-75 b up to 48 weeks (intent-to-treat population, non-responder imputation analysis). The initial baseline value was the last valid value prior to the first injection of study treatment of the initial period. The initial period was from day 1/baseline to W16. For non-responder imputation, patients with data collected after use of rescue therapy or with missing data at a visit were considered non-responders. a Investigator’s Global Assessment success was defined as 0/1 [clear/almost clear] and a ≥2-point reduction on the IGA scale from the initial baseline. b EASI-75 was defined as ≥75% improvement in EASI from the initial baseline. CI: confidence interval; EASI: Eczema Area and Severity Index; IGA: Investigator’s Global Assessment; Q4/8W: every 4/8 weeks.

IGA_success

IGA success

Fig. 1. · Panel IGA_success

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel IGA_success 是同一 Fig. 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 3 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
EASI-75

EASI-75

Fig. 1. · Panel EASI-75

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel EASI-75 是同一 Fig. 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 2.Response rate for EASI-50 a and EASI-90 a up to 48 weeks (intent-to-treat population, non-responder imputation analysis). The initial baseline value was the last valid value prior to the first injection of study treatment of the initial period. The initial period was from day 1/baseline to W16. For NRI, patients with data collected after use of rescue therapy or with missing data at a visit were considered non-responders. a EASI-50/90 was defined as ≥50%/≥90% improvement in EASI from the initial baseline. CI: confidence interval; EASI: Eczema Area and Severity Index; Q4/8W: every 4/8 weeks.
非 KM Figure
Fig. 3.Change from maintenance baseline in weekly average PP NRS (intent-to-treat population, multiple imputation-missing at random analysis). W16 measurement served as maintenance baseline measurements. If W16 measurements were missing, the last valid nonmissing measurements prior to W16 were taken as the maintenance baseline measurement. The analysis of variance model was used for the change from the maintenance baseline as the dependent variable, including treatment group and study as factors, and the maintenance baseline PP NRS as a covariate. If a patient received any rescue therapy, the data after receipt of rescue therapy were imputed to the worst possible value.CI: confidence interval; LSM: least squares mean; PP NRS: Peak Pruritus Numerical Rating Scale; Q4W: every 4 weeks; Q8W: every 8 weeks.
非 KM Figure